Go Pro
NASDAQ:ACON

Aclarion Q1 2026 Earnings Report

Aclarion logo
$2.62 +0.04 (+1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$2.47 -0.15 (-5.65%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclarion EPS Results

Actual EPS
-$1.34
Consensus EPS
-$1.55
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.03 million
Beat/Miss
Missed by -$3.86 thousand
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Aclarion's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Aclarion Earnings Headlines

They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

View Aclarion Profile